Farshad Guirakhoo
Overview
Explore the profile of Farshad Guirakhoo including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
40
Citations
1126
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Wang S, Guirakhoo F, Periasamy S, Ryan V, Wiggins J, Subramani C, et al.
Vaccines (Basel)
. 2024 Jan;
12(1).
PMID: 38250853
Antibodies provide critical protective immunity against COVID-19, and the Fc-mediated effector functions and mucosal antibodies also contribute to the protection. To expand the characterization of humoral immunity stimulated by subunit...
2.
Wang S, Wang C, Kuo H, Peng W, Huang J, Kuo B, et al.
Emerg Microbes Infect
. 2022 Oct;
11(1):2724-2734.
PMID: 36287714
The development of safe and effective vaccines to respond to COVID-19 pandemic/endemic remains a priority. We developed a novel subunit protein-peptide COVID-19 vaccine candidate (UB-612) composed of: (i) receptor binding...
3.
Malherbe D, Domi A, Hauser M, Atyeo C, Fischinger S, Hyde M, et al.
NPJ Vaccines
. 2022 Jul;
7(1):83.
PMID: 35879311
A new vectored vaccine MVA-VLP-SUDV was generated against Sudan ebolavirus (SUDV) combining the advantages of the immunogenicity of a live attenuated vaccine vector (Modified Vaccinia Ankara, MVA) with the authentic...
4.
Guirakhoo F, Wang S, Wang C, Kuo H, Peng W, Liu H, et al.
J Infect Dis
. 2022 Jun;
226(8):1401-1406.
PMID: 35723969
The highly transmissible severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) Omicron variant has caused high rates of breakthrough infections in those previously vaccinated with ancestral strain coronavirus disease 2019 (COVID-19)...
5.
Wang C, Hwang K, Kuo H, Peng W, Shen Y, Kuo B, et al.
J Clin Invest
. 2022 Mar;
132(10).
PMID: 35316221
BackgroundThe Delta and Omicron variants of SARS-CoV-2 are currently responsible for breakthrough infections due to waning immunity. We report phase I/II trial results of UB-612, a multitope subunit vaccine containing...
6.
Malherbe D, Domi A, Hauser M, Meyer M, Gunn B, Alter G, et al.
NPJ Vaccines
. 2020 Sep;
5(1):78.
PMID: 32922962
We introduce a new vaccine platform against Marburg virus (MARV) combining the advantages of the immunogenicity of a highly attenuated vaccine vector (Modified Vaccinia Ankara, MVA) with the authentic conformation...
7.
Salvato M, Domi A, Guzman-Cardozo C, Medina-Moreno S, Zapata J, Hsu H, et al.
Pathogens
. 2019 Aug;
8(3).
PMID: 31466243
Lassa fever surpasses Ebola, Marburg, and all other hemorrhagic fevers except Dengue in its public health impact. Caused by Lassa virus (LASV), the disease is a scourge on populations in...
8.
Domi A, Feldmann F, Basu R, McCurley N, Shifflett K, Emanuel J, et al.
Sci Rep
. 2018 Jan;
8(1):864.
PMID: 29339750
Ebola virus (EBOV), isolate Makona, was the causative agent of the West African epidemic devastating predominantly Guinea, Liberia and Sierra Leone from 2013-2016. While several experimental vaccine and treatment approaches...
9.
A Zika Vaccine Targeting NS1 Protein Protects Immunocompetent Adult Mice in a Lethal Challenge Model
Brault A, Domi A, McDonald E, Talmi-Frank D, McCurley N, Basu R, et al.
Sci Rep
. 2017 Nov;
7(1):14769.
PMID: 29116169
Zika virus (ZIKV) is a mosquito-borne flavivirus that has rapidly extended its geographic range around the world. Its association with abnormal fetal brain development, sexual transmission, and lack of a...
10.
Duggal N, Ritter J, McDonald E, Romo H, Guirakhoo F, Davis B, et al.
Am J Trop Med Hyg
. 2017 Aug;
97(5):1410-1417.
PMID: 28820694
Although first isolated almost 70 years ago, Zika virus (ZIKV; ) has only recently been associated with significant outbreaks of disease in humans. Several severe ZIKV disease manifestations have also...